Jeremy H Pettus

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5266963/publications.pdf

Version: 2024-02-01

		218381	182168
53	2,900	26	51
papers	citations	h-index	g-index

54	54	54	3106
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Risk of <scp>newâ€onset</scp> type 2 diabetes in 600â€‰055 people after <scp>COVID</scp>â€19: A cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 1176-1179.	2.2	28
2	SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes. Diabetes, 2022, 71, 511-519.	0.3	4
3	Impact of the hepatoselective glucokinase activator <scp>TTP399</scp> on ketoacidosis during insulin withdrawal in people with type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 1439-1447.	2.2	2
4	Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. Primary Care Diabetes, 2021, 15, 199-207.	0.9	13
5	A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. Diabetes Technology and Therapeutics, 2021, 23, 367-375.	2.4	80
6	Demographic characteristics and acute complications among adults with type 1 diabetes: Comparison of two multicentre databases from Germany and the United States. Journal of Diabetes and Its Complications, 2021, 35, 107812.	1.2	3
7	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care, 2021, 44, 1595-1603.	4.3	41
8	Anti-interleukin-21 antibody and liraglutide for the preservation of Î²-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 212-224.	5.5	85
9	Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemicâ€™s Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526â€“532. Diabetes Care, 2021, 44, e103-e104.	4.3	3
10	Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2021, 44, 2286-2292.	4.3	4
11	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2021, 44, 2589-2625.	4.3	244
12	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2021, 64, 2609-2652.	2.9	128
13	COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemicâ€™s Impact in Type 1 and Type 2 Diabetes. Diabetes Care, 2021, 44, 526-532.	4.3	202
14	Importance of diabetes management during the COVID-19 pandemic. Postgraduate Medicine, 2021, 133, 912-919.	0.9	8
15	Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Medicine, 2021, 2, 100466.	3.3	126
16	Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes Care, 2020, 43, 161-168.	4.3	24
17	Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A realâ€world study of more than 30â€‰000 patients in a US electronic health record database. Diabetes, Obesity and Metabolism, 2020, 22, 622-630.	2.2	20
18	Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 311-318.	0.5	7

#	Article	IF	Citations
19	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. Diabetes Research and Clinical Practice, 2020, 165, 108235.	1.1	20
20	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 471-477.	2.4	17
21	Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies. Diabetes, 2019, 68, 1886-1891.	0.3	6
22	Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures. Diabetes Technology and Therapeutics, 2019, 21, 336-343.	2.4	9
23	Efficacy and safety of a morning injection of insulin glargine 300â€‰units/mL versus insulin glargine 100â€‰units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. Diabetes, Obesity and Metabolism, 2019, 21, 1906-1913.	2.2	9
24	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
25	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. Diabetes Therapy, 2019, 10, 617-633.	1.2	50
26	Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study. Diabetes Care, 2019, 42, 2220-2227.	4.3	93
27	Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 812-821.	2.2	117
28	Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgraduate Medicine, 2018, 130, 375-380.	0.9	9
29	Effect of a glucagon receptor antibody (REMDâ€477) in type 1 diabetes: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1302-1305.	2.2	50
30	The shifting paradigm of a â€œcureâ€•for type 1 diabetes: is technology replacing immune-based therapies?. Acta Diabetologica, 2018, 55, 117-120.	1.2	4
31	Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. Diabetes Care, 2018, 41, 2265-2274.	4.3	120
32	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
33	Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Technology and Therapeutics, 2018, 20, 715-724.	2.4	49
34	Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 133-148.	1.1	21
35	Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2018, 20, 448-451.	2.4	11
36	Initial Clinical Evaluation of VC-01TM Combination Productâ€”A Stem Cellâ€“Derived Islet Replacement for Type 1 Diabetes (T1D). Diabetes, 2018, 67, .	0.3	63

#	Article	IF	Citations
37	Dapagliflozin in patients with type 1 diabetes: <scp>A</scp>post hoc analysis of the effect of insulin dose adjustments on 24â€hour continuously monitored mean glucose and fasting Î²â€hydroxybutyrate levels in a phase <scp>IIa</scp> pilot study. Diabetes, Obesity and Metabolism, 2017, 19, 814-821.	2.2	34
38	Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Current Medical Research and Opinion, 2017, 33, 1821-1831.	0.9	31
39	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
40	Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 138-147.	1.3	92
41	Time To Get Serious About Insulin Timing. Endocrine Practice, 2017, 23, 503-505.	1.1	4
42	Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes, Obesity and Metabolism, 2016, 18, 463-474.	2.2	12
43	Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes. Journal of Diabetes Science and Technology, 2016, 10, 793-798.	1.3	26
44	Differences in Use of Glucose Rate of Change (ROC) Arrows to Adjust Insulin Therapy Among Individuals With Type 1 and Type 2 Diabetes Who Use Continuous Glucose Monitoring (CGM). Journal of Diabetes Science and Technology, 2016, 10, 1087-1093.	1.3	19
45	The past, present, and future of basal insulins. Diabetes/Metabolism Research and Reviews, 2016, 32, 478-496.	1.7	63
46	How Patients With Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions. Endocrine Practice, 2015, 21, 613-620.	1.1	57
47	Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects. Diabetes Care, 2014, 37, 2609-2615.	4.3	54
48	Testing versus guessing blood glucose values: impact on self-care behaviors in type 2 diabetes. Current Medical Research and Opinion, 2014, 30, 1795-1802.	0.9	5
49	Challenges Associated with Insulin Therapy inÂType 2 Diabetes Mellitus. American Journal of Medicine, 2014, 127, S11-S16.	0.6	47
50	CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. Journal of Autoimmunity, 2014, 50, 77-82.	3.0	69
51	GLP-1 agonists in type 1 diabetes. Clinical Immunology, 2013, 149, 317-323.	1.4	39
52	Temporal Intra-Individual Variation of Immunological Biomarkers in Type 1 Diabetes Patients: Implications for Future Use in Cross-Sectional Assessment. PLoS ONE, 2013, 8, e79383.	1.1	3
53	Differences Between Perceived Versus Measured Blood Glucose Test Results in People With Type 2 Diabetes. Canadian Journal of Diabetes, 2012, 36, S43-S44.	0.4	1